PMID- 38178048
OWN - NLM
STAT- MEDLINE
DCOM- 20240108
LR  - 20240108
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Jan 4
TI  - Sustained effort network for treatment of status epilepticus/European academy of 
      neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE).
PG  - 19
LID - 10.1186/s12883-023-03505-y [doi]
LID - 19
AB  - BACKGROUND: Status Epilepticus (SE) is a common neurological emergency associated 
      with a high rate of functional decline and mortality. Large randomized trials 
      have addressed the early phases of treatment for convulsive SE. However, evidence 
      regarding third-line anesthetic treatment and the treatment of nonconvulsive 
      status epilepticus (NCSE) is scarce. One trial addressing management of 
      refractory SE with deep general anesthesia was terminated early due to 
      insufficient recruitment. Multicenter prospective registries, including the 
      Sustained Effort Network for treatment of Status Epilepticus (SENSE), have shed 
      some light on these questions, but many answers are still lacking, such as the 
      influence exerted by distinct EEG patterns in NCSE on the outcome. We therefore 
      initiated a new prospective multicenter observational registry to collect 
      clinical and EEG data that combined may further help in clinical decision-making 
      and defining SE. METHODS: Sustained effort network for treatment of status 
      epilepticus/European Academy of Neurology Registry on refractory Status 
      Epilepticus (SENSE-II/AROUSE) is a prospective, multicenter registry for patients 
      treated for SE. The primary objectives are to document patient and SE 
      characteristics, treatment modalities, EEG, neuroimaging data, and outcome of 
      consecutive adults admitted for SE treatment in each of the participating centers 
      and to identify factors associated with outcome and refractoriness. To reach 
      sufficient statistical power for multivariate analysis, a cohort size of 3000 
      patients is targeted. DISCUSSION: The data collected for the registry will 
      provide both valuable EEG data and information about specific treatment steps in 
      different patient groups with SE. Eventually, the data will support clinical 
      decision-making and may further guide the planning of clinical trials. Finally, 
      it could help to redefine NCSE and its management. TRIAL REGISTRATION: NCT 
      number: NCT05839418.
CI  - (c) 2024. The Author(s).
FAU - Damien, Charlotte
AU  - Damien C
AD  - Department of Neurology, Hopital Universitaire de Bruxelles, Hopital Erasme, 
      Brussels, Belgium.
FAU - Leitinger, Markus
AU  - Leitinger M
AD  - Department of Neurology Neurointensive Care and Neurorehabilitation, Centre for 
      Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical 
      University, European Reference Network EpiCARE, Salzburg, Austria.
AD  - Neuroscience Institute, Department of Neurology, Centre for Cognitive 
      Neuroscience, Christian Doppler University Hospital, Paracelsus Medical 
      University, Salzburg, Austria.
FAU - Kellinghaus, Christoph
AU  - Kellinghaus C
AD  - Epilepsy Center Munster-Osnabruck, Klinikum Osnabruck, Osnabruck, Germany.
FAU - Strzelczyk, Adam
AU  - Strzelczyk A
AD  - Department of Neurology and Epilepsy Center Frankfurt Rhine-Main, 
      Goethe-University and University Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - De Stefano, Pia
AU  - De Stefano P
AD  - EEG & Epilepsy Unit, Department of Clinical Neurosciences, University Hospital of 
      Geneva, Geneva, Switzerland.
AD  - Neuro-Intensive Care Unit, Department of Intensive Care, University Hospital of 
      Geneva, Geneva, Switzerland.
FAU - Beier, Christoph P
AU  - Beier CP
AD  - Department of Neurology, Odense University Hospital, Odense, Denmark.
FAU - Sutter, Raoul
AU  - Sutter R
AD  - Department of Neurology, University Hospital Basel, Basel, Switzerland.
AD  - Intensive Care Units, University Hospital Basel, Basel, Switzerland.
FAU - Kamppi, Leena
AU  - Kamppi L
AD  - Department of Neurology, Epilepsia Helsinki, Helsinki University Hospital and 
      University of Helsinki, Helsinki, Finland.
FAU - Strbian, Daniel
AU  - Strbian D
AD  - Department of Neurology, Epilepsia Helsinki, Helsinki University Hospital and 
      University of Helsinki, Helsinki, Finland.
FAU - Tauboll, Erik
AU  - Tauboll E
AD  - Department of Neurology, Oslo University Hospital, Oslo, Norway.
FAU - Rosenow, Felix
AU  - Rosenow F
AD  - Department of Neurology and Epilepsy Center Frankfurt Rhine-Main, 
      Goethe-University and University Hospital Frankfurt, Frankfurt am Main, Germany.
FAU - Helbok, Raimund
AU  - Helbok R
AD  - Department of Neurology, Johannes Kepler University Linz, Linz, Austria.
FAU - Ruegg, Stephan
AU  - Ruegg S
AD  - Department of Neurology, Epilepsia Helsinki, Helsinki University Hospital and 
      University of Helsinki, Helsinki, Finland.
FAU - Damian, Maxwell
AU  - Damian M
AD  - Department of Critical Care, Essex Cardiothoracic Centre, Basildon, UK.
FAU - Trinka, Eugen
AU  - Trinka E
AD  - Department of Neurology Neurointensive Care and Neurorehabilitation, Centre for 
      Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical 
      University, European Reference Network EpiCARE, Salzburg, Austria.
AD  - Neuroscience Institute, Department of Neurology, Centre for Cognitive 
      Neuroscience, Christian Doppler University Hospital, Paracelsus Medical 
      University, Salzburg, Austria.
AD  - Karl Landsteiner Institute of Neurorehabilitation and Space Neurology, Salzburg, 
      Austria.
AD  - Department of Public Health, Health Services Research and Health Technology 
      Assessment, UMIT - University for Health Sciences, Medical Informatics and 
      Technology, Hall en Tyrol, Austria.
FAU - Gaspard, Nicolas
AU  - Gaspard N
AD  - Department of Neurology, Hopital Universitaire de Bruxelles, Hopital Erasme, 
      Brussels, Belgium. Nicolas.Gaspard@hubruxelles.be.
AD  - Department of Neurology, Yale University School of Medicine, New Haven, CT, USA. 
      Nicolas.Gaspard@hubruxelles.be.
LA  - eng
SI  - ClinicalTrials.gov/NCT05839418
GR  - 320030_169379/Swiss National Foundation/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20240104
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Prospective Studies
MH  - *Status Epilepticus/diagnosis/drug therapy
MH  - Multivariate Analysis
MH  - Registries
MH  - Electroencephalography
MH  - Anticonvulsants/therapeutic use
PMC - PMC10765797
OTO - NOTNLM
OT  - Anti-seizure medication
OT  - Continuous intravenous anesthetic Drugs
OT  - EEG
OT  - Outcome
OT  - Refractoriness
OT  - Status Epilepticus
COIS- Christoph Kellinghaus has received speaker's honoraria from Angelini Pharma, 
      Eisai, Jazz Pharmaceuticals, UCB, LivaNova. He has served on advisory boards for 
      Angelini Pharma, Eisai and Marinus Pharma. Adam Strzelczyk received personal fees 
      and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz (GW) 
      Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB (Zogenix) Pharma, and 
      UNEEG medical. AS is editor-in-chied of Clinical Epileptology and editorial board 
      member of Neurological Research and Practice. Raoul Sutter received research 
      grants from the Swiss National Foundation (No 320030_169379), the Research Fund 
      of the University Basel, the Scientific Society Basel, and the Gottfried Julia 
      Bangerter-Rhyner Foundation. He received personal grants from UCB-pharma and 
      holds stocks from Novartis, Roche, Alcon, and Johnson & Johnson. Leena Kamppi 
      reports speaker's honoraria from UCB, Merck and Eisai and personal grants from 
      Michael Foundation, Finnish Neurological Society, Finnish Cultural Foundation and 
      HUS Neurocenter. Daniel Strbian serves in the advisory board for AstraZeneca, 
      Alexion, Janssen, BMS, Orion, CLS Behring, Herantis Pharma and received 
      unrestricted education grant from Boehringer Ingelheim. Stephan Ruegg has 
      received honoraria from serving on the scientific advisory boards of 
      Arvelle/Angelini, Bial, Eisai, GW, and UCB-pharma, and from serving as a 
      consultant for Arvelle/Angelini, Eisai, Pfizer, Novartis, Sandoz, and UCB-pharma. 
      He has received speaker's honoraria from Eisai and Novartis. He does not hold any 
      stocks of any pharmaceutical industries or manufacturers of medical devices. He 
      disclosed that he is co-editor-in-chief of Clinical Epileptology (01/01/2022; no 
      payments). Eugen Trinka reports paid consultancy from Arvelle, Argenx, Angelini, 
      Clexio, UCB, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Jazz, 
      Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals/Jazz, Marinus; Research 
      funding (directly, or to institution) from GSK, Biogen, Eisai, Novartis, Red 
      Bull, Bayer, and UCB; Speaker's honoraria from Arvelle, Angelini, GSK, GW 
      Pharmaceuticals, Bohringer Ingelheim, Eisai, Epilog, Bial, Everpharma, UCB, 
      Liva-Nova, Newbridge, Hikma, Novartis, and Sanofi. He is CEO of Neuroconsult 
      Ges.m.b.H. Grants from Austrian Science Fund (FWF), Osterreichische Nationalbank, 
      and the European Union. Nicolas Gaspard reports speaker's honoraria from UCB 
      Pharma and Angelini Pharma; paid consultancy from UCB Pharma and Marinus and 
      research funding (directly, or to institution) from UCB and Angelini; grants from 
      Belgian National Research Fund; Fonds Erasme pour la Recherche Medicale and 
      INNOVIRIS; honoraria from MedLink Neurology. Other authors declare that they have 
      no competing interest.
EDAT- 2024/01/05 00:42
MHDA- 2024/01/08 06:43
PMCR- 2024/01/04
CRDT- 2024/01/04 23:42
PHST- 2023/07/14 00:00 [received]
PHST- 2023/12/11 00:00 [accepted]
PHST- 2024/01/08 06:43 [medline]
PHST- 2024/01/05 00:42 [pubmed]
PHST- 2024/01/04 23:42 [entrez]
PHST- 2024/01/04 00:00 [pmc-release]
AID - 10.1186/s12883-023-03505-y [pii]
AID - 3505 [pii]
AID - 10.1186/s12883-023-03505-y [doi]
PST - epublish
SO  - BMC Neurol. 2024 Jan 4;24(1):19. doi: 10.1186/s12883-023-03505-y.